766,051 Shares in Precision BioSciences, Inc. (NASDAQ:DTIL) Acquired by Lynx1 Capital Management LP

Lynx1 Capital Management LP acquired a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 766,051 shares of the company's stock, valued at approximately $2,919,000. Precision BioSciences makes up approximately 1.1% of Lynx1 Capital Management LP's portfolio, making the stock its 12th biggest holding. Lynx1 Capital Management LP owned 9.99% of Precision BioSciences at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Commonwealth Equity Services LLC bought a new stake in Precision BioSciences in the fourth quarter worth $48,000. Samalin Investment Counsel LLC acquired a new position in shares of Precision BioSciences during the 4th quarter valued at about $59,000. XTX Topco Ltd acquired a new stake in Precision BioSciences in the 4th quarter worth approximately $67,000. Geode Capital Management LLC raised its position in shares of Precision BioSciences by 40.7% in the third quarter. Geode Capital Management LLC now owns 65,974 shares of the company's stock valued at $591,000 after purchasing an additional 19,088 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Precision BioSciences by 36.2% in the fourth quarter. Renaissance Technologies LLC now owns 109,798 shares of the company's stock worth $418,000 after buying an additional 29,200 shares during the last quarter. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on DTIL shares. BMO Capital Markets upgraded shares of Precision BioSciences from a "market perform" rating to an "outperform" rating and set a $34.00 price objective on the stock in a research note on Friday, January 10th. HC Wainwright reissued a "buy" rating and set a $60.00 target price on shares of Precision BioSciences in a research report on Friday, March 28th.

Precision BioSciences Price Performance

Shares of Precision BioSciences stock traded up $0.17 during trading on Friday, hitting $5.89. 85,716 shares of the company's stock traded hands, compared to its average volume of 181,411. Precision BioSciences, Inc. has a twelve month low of $3.61 and a twelve month high of $13.44. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The company has a market cap of $62.09 million, a PE ratio of 98.10 and a beta of 1.59. The firm's fifty day moving average price is $5.03 and its 200 day moving average price is $5.76.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($3.20) EPS for the quarter, missing the consensus estimate of ($2.09) by ($1.11). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The company had revenue of $3.47 million during the quarter, compared to analyst estimates of $4.28 million. Analysts forecast that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.

Precision BioSciences Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.